Showing results (41-50 of 433) with videos related to
Sort By:
Pageof 44
Cardiovascular Research|August 12, 2003
Influence of differential vascular remodeling on the coronary vasomotor responseAndrew L McLeod, David E Newby, David B Northridge, et al.International Journal of Cardiology|December 13, 2018
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI populationFrançois Schiele, Etienne Puymirat, Jean Ferrières, et al.Journal of the American College of Cardiology|May 11, 2019
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS TrialKeith A A Fox, John W Eikelboom, Olga Shestakovska, et al.Circulation|February 4, 2010
Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromesClara K Chow, Sanjit Jolly, Purnima Rao-Melacini, et al.Circulation|August 16, 2006
Adverse impact of bleeding on prognosis in patients with acute coronary syndromesJohn W Eikelboom, Shamir R Mehta, Sonia S Anand, et al.Journal of the American College of Cardiology|January 18, 2005
Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3)Joseph Kim, Robert A Henderson, Stuart J Pocock, et al.Hypertension (Dallas, Tex. : 1979)|October 20, 2004
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibitionNicholas L M Cruden, Keith A A Fox, Christopher A Ludlam, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|April 24, 2004
Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failureNicholas L M Cruden, Fraser N Witherow, David J Webb, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|July 19, 2003
Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humansFraser N Witherow, Pamela Dawson, Christopher A Ludlam, et al.Alimentary Pharmacology & Therapeutics|July 2, 2024
Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trialNauzer Forbes, Qilong Yi, Paul Moayyedi, et al.Pageof 44